| Document |
Document Title |
|
JPH0524918B2 |
Compounds I (R = H, CH3; R1 = H, halogen, CH3, phenylthio, C1 - C4 alkylthio; R2 = H, CH3O and R3 = H or R2 + R3 = chemical bond; R4 = C1 - C4 hydrocarbon; R5, R6, R8, R9 independently = H, C1 - C4 alkyl or R5, R8 independently = H, C1 -...
|
|
JPH0558976A |
PURPOSE: To obtain a new compd. which is useful as pharmaceutics having pharmaceutical activity for central nervous system and peripheral nervous system. CONSTITUTION: The compd. expressed by the formula or its salts are used. In the for...
|
|
JPH0558912A |
PURPOSE: To obtain the composition comprising a peripheral dopaminergic substance such as an ergoline derivative, a carrier and a vehicle and useful for completely reducing the propagation of rodents such as mice, rats and rabbits. CONST...
|
|
JPH0512329B2 |
Organic amide compounds of the formula wherein R1-CO is a residue of a carboxylic acid with the proviso that the carboxylic acid is not a natural fatty acid normally bound to nitrogen of nitrogenous lipids, R2 is a hydrogen atom, a C1-7 ...
|
|
JPH0465066B2 |
|
|
JPH0462316B2 |
The invention relates to novel 2-halogenated 8- and 1,8-substituted ergolene derivatives of the formula (I) and the acid addition salts thereof, pharmaceutical compositions containing them and a process for their preparation. In the form...
|
|
JPH04257583A |
PURPOSE: To provide a novel ergoline deriv. which has dopamine antagonistic activity and is useful as a therapeutic medicine for schizophrenia. CONSTITUTION: The compd. in the form of free base or acid additive salt of formula I (R1 is H...
|
|
JPH04235129A |
PURPOSE: To inhibit the demineralization of bone in mammals by administrating an effective quantity of a certain kind of ergoline analog. CONSTITUTION: This inhibitor contains a compound of the formula [X is CH and N; Y is O and S; R<1> ...
|
|
JPH04504582A |
PCT No. PCT/EP91/00104 Sec. 371 Date Sep. 25, 1991 Sec. 102(e) Date Sep. 25, 1991 PCT Filed Jan. 21, 1991 PCT Pub. No. WO91/11447 PCT Pub. Date Aug. 8, 1991.Ergoline derivatives of the formula I: I wherein R represents hydrogen or C1-C4 ...
|
|
JPH04224578A |
PURPOSE: To provide a stereochemically pure new ergoline-8-carboxamide derivative which is useful as a strong 5HT2 receptor blocking agent for the treatment of the diseases mainly caused by an excess serotonin (5HT) of the central nervou...
|
|
JPH04221381A |
PURPOSE: To provide the subject new compound which has high dopamine- operating activity as an anti-Parkinson disease agent, and which is free from side action because it acts on only the central receptor which is changed by extrapyramid...
|
|
JPH04504425A |
Described are compounds of the formula (I) and their acid addition salts, in which R?2, R?6, R?13 and X have the meaning given in the application, plus a method of preparing the compounds and drugs containing them.
|
|
JPH0437079B2 |
(2-Haloergolinyl)-N',N'-diethylurea derivatives of Formula I (I) and the salts thereof, wherein R is hydrogen, alkyl of up to 6 carbon atoms, or alkenyl of up to 3 carbon atoms, X is halogen, is a CC single or CC double bond, and the ure...
|
|
JPH04500681A |
8 alpha -acylamino ergolines are useful dopamine agonists.
|
|
JPH03505587A |
PCT No. PCT/DE90/00282 Sec. 371 Date Dec. 21, 1990 Sec. 102(e) Date Dec. 21, 1990 PCT Filed Apr. 6, 1990 PCT Pub. No. WO90/12796 PCT Pub. Date Nov. 1, 1990.Compounds of formula I I in which R2 means optionally substituted C1-7 alkyl, C2-...
|
|
JPH0369911B2 |
|
|
JPH0368008B2 |
The invention relates to pharmaceutical compositions with a neuroleptic action and to a process for preparng these compositions.The active ingredients of the compositions of the invention are 2-halo-6-methyl-9-ergolene derivatives of for...
|
|
JPH0367067B2 |
A process for preparing lysergic acid esters of the formula wherein R is alkyl of up to 3 carbon atoms, comprises reacting corresponding lysergic acid or isolysergic acid amides with corresponding alcohols at temperatures of 0 DEG to 65 ...
|
|
JPH0366306B2 |
Novel N-substituted ergoline- and 9,10-didehydro-8-carboxamide- and -8-aminomethyl-derivatives for the treatment of vascular headaches, especially migraine, and of orthostatic hypotension.
|
|
JPH03209378A |
NEW MATERIAL: A compound of formula I [R2 is halogen, 1-4C alkyl, 2-4C alkenyl; R6 is 2-6C alkyl, 3-6C alkenyl, 3-5C cycloalkyl-1-2C alkyl; X is H, hydroxy, 1-6C acyloxy] and their acid adducts. EXAMPLE: 8,9-Didehydro2,8-dimethyl6-n-prop...
|
|
JPH03503886A |
Substituted ergolines of general formula (I), and their acid addition salts, in which (a) and (b) denote a C-C single bond or a C=C double bond, X denotes oxygen or sulphur, R1? denotes amino, nitro or the (c) residue, R2? denotes methyl...
|
|
JPH0354668B2 |
There are provided ergoline compounds of the formula: (I) wherein R1 is a hydrogen atom or a methyl group; R2 is a hydrogen or halogen atom, a methyl or thiomethyl group; R3 is a hydrogen atom or a methoxy group; R4 is a hydrocarbon grou...
|
|
JPH0352463B2 |
Ergolinyl compounds which are nitrogen-substituted in the 8-position and have Formula (I)and physiologically compatible salts thereof, wherein the 8-substituent can be in the a- or β-position andrepresents a single or a double bond. R2 ...
|
|
JPH0352446B2 |
Trans-dihydrolisuride, N-(D-6-methyl-8-isoergolin-1-yl)-N min N-diethylurea, is a useful antipsychotic, e.g., for treatment of schizophrenia and is free from the usual side effects associated with neuroleptics.
|
|
JPH0346471B2 |
The invention relates to N,N-diethyl-N'-[(8 alpha )-1-isopropyl-6-methylergolin-8-yl]sulphamide and its preparation by N-alkylation. The compound is notable in particular for its action in stimulating dopamine receptors.
|
|
JPH03502802A |
Compounds of the formula I wherein n is 1 or 2, R1 represents a hydrogen atom or a C1-C4 alkyl group, R2 represents a hydrogen atom and R3 represents a hydrogen atom or a hydroxy group or R2 and R3 together represent a chemical bond, R4 ...
|
|
JPH0342274B2 |
The subject matter of the application are pyrazole derivatives with an ergoline skeleton of general formula wherein x...y stands for a group of formula R means a hydrogen atom or a methyl group, R1 represents a hydrogen atom or a C1-4-al...
|
|
JPH0342279B2 |
|
|
JPH03128374A |
PURPOSE: To provide dihydrolysergol stereoselectively with high purity, by hydrogenation of lysergol over a Pd catalyst carried on activated carbon in the presence of a specific aprotic solvent. CONSTITUTION: Lysergol (9,10-didehydro-8β...
|
|
JPH03120277A |
NEW MATERIAL: A compound of formula I [R2 is 1-6 C alkyl, 2-6 C alkenyl, CH2-O-, 1-4 C alkyl; R4 is H, Br; R6 is 2-6 C alkyl, 3-6 C alkenyl or the like; R8 is α-NH-CX-R3 (X is O, S; R3 is H, 1-6 C alkyl or the like), CH2-Y (Y is H, OH, ...
|
|
JPH0321030B2 |
|
|
JPH0243752B2 |
|
|
JPH02233680A |
PURPOSE: To obtain a therapeutic agent against hypertension, hemicrania, vasospasm, depression, etc., containing 1-isopropyldihydrolysergic acid as the active ingredient and containing a pharmaceutically acceptable carrier. CONSTITUTION:...
|
|
JPH0240647B2 |
|
|
JPH0240044B2 |
|
|
JPH0239511B2 |
A process for preparing an ergoline of the formula wherein C9----C10 is a CC single or double bond, R1 is hydrogen or CONR2, R being hydrogen, methyl, or ethyl, and wherein NR' is in the alpha - or beta - position, R2 is lower alkyl of u...
|
|
JPH02218682A |
NEW MATERIAL: Compounds of formula I (R1 is 1-4C alkyl; R2 is aryl, 1-4C linear alkyl; R3 is H, 1-4 linear alkyl; R4 is pyridinyl, imidazolyl; alk is 1-5C alkane and a derived divalent organic group). EXAMPLE: (8β)-n-[(3-Pyridinyl)methy...
|
|
JPH02209854A |
PURPOSE: To obtain an HIV protease inhibitor contg. a specified peptide structure as active ingredient and useful for the prevention and treatment of infection of HIV, and the treatment of AIDS caused by HIV. CONSTITUTION: HIV protease i...
|
|
JPH0234345B2 |
PURPOSE:To readily and efficiently obtain norchanoclavine or norisochanoclavine useful as medicines or intermediates therefore having an ergot alkaloid skeletal structure, by reducing a nitro compound corresponding to the aimed compound ...
|
|
JPH0234346B2 |
PURPOSE:To readily and efficiently obtain chanoclavine or isochanoclavine useful as medicines and intermediates therefor having an ergot alkaloid skeletal structure, by reducing a novel carbamate derivative corresponding to the aimed com...
|
|
JPH0234344B2 |
NEW MATERIAL:1,3,4,5-Tetrahydrobenz[cd]indole derivative expressed by formula I (either one of R<1> and R<2> represents 1-3C alkyl substituted by hydroxyl or lower alkoxyl or formyl and the other represents 1-6C alkyl; R<3> represents ni...
|
|
JPH0234347B2 |
|
|
JPH02169590A |
PURPOSE: To obtain lysergic acid of high purity, which is useful as a starting substance for medicines, by bringing an aqueous lysergic acid solution resulting from alkaline hydrolysis of ergot alkaloid into contact with a specific porou...
|
|
JPH02167091A |
PURPOSE: To produce the title compound which is used as a medicine or the like in high purity and high yield by bringing a fermentation mixture containing ergnot alkaloid which is prepared by culturing Claviceps paspali in a medium into ...
|
|
JPH02142790A |
NEW MATERIAL: A compound of formula I [wherein dotted lines are each a single bond or a double bond; X is O or S; R2 is 1-10C alkyl, (halogen- substituted) 2-10C alkenyl, CH2YR3 (wherein R3 is H, 1-4C alkyl, phenyl, etc.; Y is O or S), C...
|
|
JPH02142789A |
PURPOSE: To obtain a 2'-, 12'- or 13'-substituted 3-(8'α-ergolinyl)-1,1-diethylurea having dopamine agonist action or dopamine antagonist action in one step in high yield by reacting a specific compound with a specific organometallic co...
|
|
JPH0210834B2 |
The invention relates to new ergol-8-ene and ergoline derivatives of the general formula /I/ /I/ wherein x y stands for -CH=C= or -CH2-CH= group, R stands for hydrogen atom or methyl group, R1 stands for hydrogen or halogen atom, R2 stan...
|
|
JPH0259580A |
NEW MATERIAL: A compd. represented by formula I {wherein R1 is a 1-4C alkyl, a 1-2C fluorinated alkyl or a 1-4C alkoxy, (n) is 0-2, Z forms 5-8 heterocyclic groups in combination with C and N, B is O, a group represented by formula II (R...
|
|
JPH01228965A |
NEW MATERIAL:Indoloquinoline, benzo[b]acridine and benzo[c]acridine of formulas IWIII. EXAMPLE: N-{4-[(Indolo[3,2-b]quinolin-10-yl)amino]-3-methoxyphenyl) methanesulfonamide. USE: Anticancer agent. PREPARATION: One of compounds of formul...
|
|
JPH01224374A |
NEW MATERIAL: Ergoline deriv. expressed by formula I with non-substituted in the 8th position and substituted in the 9th position in an isolated base or acid-added salt state. In the formula I, R1 is H, 1 to 4C alkyl; R2 is furanyl, phen...
|
